For this reason, we monitored PTEN and Akt activities in seven cancer cell lines in the short-term following a single treatment with rec-TF or PAR2-AP, as well as examining the outcome of exposure of cells to repeated doses of TF over longer periods. This evidence concerns the gene PTEN and cancer.